TY - JOUR T1 - Impact of aortic valve replacement in symptomatic low-risk patients with less than severe aortic stenosis JF - Open Heart JO - Open Heart DO - 10.1136/openhrt-2023-002297 VL - 10 IS - 1 SP - e002297 AU - Saki Ito AU - Roger Laham AU - Vuyisile T Nkomo AU - John K Forrest AU - Michael J Reardon AU - Stephen H Little AU - Mubashir Mumtaz AU - Hemal Gada AU - Tanvir Bajwa AU - David Langholz AU - John Heiser AU - Atul Chawla AU - Bart Jenson AU - Guilherme Attizanni AU - Alan H Markowitz AU - Jian Huang AU - Jae K Oh Y1 - 2023/05/01 UR - http://openheart.bmj.com/content/10/1/e002297.abstract N2 - Objective To evaluate whether transcatheter or surgical aortic valve replacement (TAVR or SAVR) affects clinical and haemodynamic outcomes in symptomatic patients with moderately-severe aortic stenosis (AS).Methods Echocardiographic evidence of severe AS for enrolment in the Evolut Low Risk trial was based on site-reported measurements. For this post hoc analysis, core laboratory measurements identified patients with symptomatic moderately-severe AS (1.0<aortic valve area (AVA)<1.5 cm2, 3.0<peak velocity<4.0 m/s and 20≤mean gradient (MG) <40 mm Hg). Clinical outcomes were reported through 2 years.Results Moderately-severe AS was identified in 113 out of 1414 patients (8%). Baseline AVA was 1.1±0.1 cm2, peak velocity 3.7±0.2 m/s, MG 32.7±4.8 mm Hg and aortic valve calcium volume 588 (364, 815) mm3. Valve haemodynamics improved following TAVR (AVA 2.5±0.7 cm2, peak velocity 1.9±0.5 m/s and MG 8.4±4.8 mm Hg; p<0.001 for all) and SAVR (AVA 2.0±0.6 cm2, peak velocity 2.1±0.4 m/s and MG 10.0±3.4 mm Hg; p<0.001 for all). At 24 months, the rates of death or disabling stroke were similar (TAVR 7.7% vs SAVR 6.5%; p=0.82). Kansas City Cardiomyopathy Questionnaire overall summary score assessing quality of life improved from baseline to 30 days after TAVR (67.0±20.6 to 89.3±13.4; p<0.001) and SAVR (67.5±19.6 to 78.3±22.3; p=0.001).Conclusions In symptomatic patients with moderately-severe AS, AVR appears to be beneficial. Determination of the clinical and haemodynamic profile of patients who can benefit from earlier isolated AVR needs further investigation in randomised clinical trials.Data are available on reasonable request. ER -